Intelligent Nanocomposite Hydrogels: Bridging Smart Design and Personalized Cancer Therapy

Shirin Dehghan[1*], Mahdi Hosseinzadeh Fomani [2], Hessan Hosseinzadeh Bandbafha[3], Mohammad Boomhendi[4], Mahla Shahbazi[5]

[1]Department of Genetics, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran, shirindehghan2021@gmail.com (responsible)*
[2]Department of Microbiology, Faculty of Biological Sciences, Central branch of Islamic Azad University, Tehran, Iran
[3]Department of Microbiology, Faculty of Biological Sciences, Central branch of Islamic Azad University, Tehran, Iran
[4]Department of Chemical Engineering, Faculty of Engineering, Kashan University, Kashan, Iran
[5]Department of Chemistry, Faculty of Chemistry Sciences, Kharazmi University, Tehran, Iran

ABSTRACT

Stimuli-responsive nanocomposite hydrogels represent a transformative class of biomaterials at the intersection of nanotechnology, polymer chemistry, and oncology. By integrating nanoscale building blocks into hydrated three-dimensional polymeric networks, these systems offer mechanical reinforcement, tunable responsiveness, and biomimetic environments that closely resemble the extracellular matrix. Among the most promising applications is cancer therapy, where the tumor microenvironment provides exploitable physicochemical cues such as acidity, temperature gradients, and redox imbalance. This review highlights the advances in temperature-sensitive, pH-sensitive, multi-stimuli responsive, and graphene-based nanocomposite hydrogels, with particular emphasis on their mechanisms of drug release, structural design, and therapeutic outcomes. Emerging strategies demonstrate superior tumor selectivity, improved pharmacokinetics, and the ability to overcome multidrug resistance compared with conventional delivery approaches. Despite significant preclinical progress, translational barriers—including safety, large-scale manufacturing, and regulatory complexities—remain formidable. Future directions will prioritize multifunctional theranostic platforms, biomimetic engineering, and sustainable material innovations to accelerate clinical adoption of these next-generation cancer nanomedicines.

Keywords: Stimuli-responsive hydrogels, nanocomposites, drug delivery, tumor microenvironment, temperature-sensitive polymers

1. INTRODUCTION

Nanocomposite hydrogels have emerged as a new generation of biomaterials that combine the structural versatility of three-dimensional polymeric networks with the functional advantages of nanoscale components [1-6]. By integrating nanoparticles into hydrogel matrices, these hybrids achieve enhanced flexibility, durability, and responsiveness, overcoming many of the intrinsic limitations of their individual constituents [3,5,7]. Depending on their composition and fabrication methods, nanocomposite hydrogels can be engineered into membranes, sponges, or fibrous structures, each tailored to specific biomedical applications. Importantly, they provide a hydrated and biocompatible environment that closely mimics the extracellular matrix (ECM), offering both mechanical support and biochemical cues essential for tissue development and regeneration [3,5,7].

The incorporation of nanoparticles adds a further layer of sophistication to these systems. Organic nanocarriers are widely exploited for drug and gene delivery, whereas inorganic nanoparticles can strengthen the hydrogel network and impart novel functionalities such as magnetic responsiveness, optical activity, or catalytic capacity [2,8,9]. When embedded within hydrogels, nanoparticles not only enhance the material's robustness but also enable spatiotemporally controlled delivery of therapeutic agents. This synergistic

combination has made nanocomposite hydrogels a promising platform for diverse applications in regenerative medicine and oncology [1,5,6].

Cancer therapy, in particular, stands to benefit significantly from these advances. Conventional systemic chemotherapy suffers from poor tumor selectivity and severe dose-limiting toxicities. The tumor microenvironment (TME), however, presents exploitable physicochemical hallmarks—such as acidic extracellular pH and locally elevated interstitial temperatures—that distinguish malignant tissue from healthy counterparts [10,11,12,13,14,15]. Stimuli-responsive polymeric nanocomposites have been designed to harness these features, releasing therapeutic payloads only under specific conditions within the TME. Among these, pH- and thermo-responsive systems are especially promising, as their underlying chemistries—ranging from lower/upper critical solution temperature transitions to acid-labile bonds—are both well understood and tunable. By restricting drug release to the tumor site, such smart materials improve therapeutic efficacy while mitigating systemic side effects, addressing long-standing challenges such as multidrug resistance and limited tumor penetration [5,16,17].

Against this backdrop, this review aims to synthesize current knowledge on the physicochemical design of stimuli-responsive nanocomposite hydrogels, highlight representative material motifs and targeting strategies, and evaluate preclinical evidence supporting their use in cancer therapy. Finally, we discuss the translational challenges that must be overcome to bring these promising materials from laboratory research to clinical reality.

1. Temperature-Sensitive Polymer Nanocomposites

Temperature-sensitive nanocomposites represent one of the most established classes of smart materials in cancer nanomedicine. Their performance is governed by the lower critical solution temperature (LCST) or, less commonly, the upper critical solution temperature (UCST) of their constituent polymers [10,11]. At temperatures below the LCST, polymers remain hydrophilic and hydrated, maintaining structural integrity and retaining their therapeutic cargo. When the temperature exceeds the LCST, the polymer becomes hydrophobic and collapses, leading to drug release. UCST systems operate inversely, with solubility increasing at higher temperatures [18,19].

The most prominent example is poly(N-isopropylacrylamide) (PNIPAM), which exhibits an LCST near physiological temperature (~32–34 °C). Through copolymerization or chemical modification, this transition can be tuned to align with the mild hyperthermia observed in tumors (~40–43 °C), or externally induced via photothermal or magnetic hyperthermia [20,21,22]. Such responsiveness enables localized, on-demand drug release in cancerous tissues while minimizing systemic exposure. Beyond PNIPAM, polymers such as Pluronics and chitosan derivatives have been incorporated into injectable hydrogels, offering both thermosensitivity and in situ gelation for sustained release [1–3].

These systems can also synergize with hyperthermia therapy itself. Localized heating not only accelerates drug release but also enhances tumor vascular permeability, improving drug penetration, and sensitizes tumor cells to chemo- and radiotherapy [16,17,20]. Thus, thermo-responsive polymer nanocomposites serve as both therapeutic carriers and enhancers of complementary cancer treatments.

2. pH-Sensitive Polymer Nanocomposites

The acidic tumor microenvironment provides another powerful internal trigger for selective drug release. While normal tissues and blood maintain a near-neutral pH (~7.4), the extracellular milieu of tumors is moderately acidic (pH ~6.5–6.9), and intracellular compartments such as endosomes and lysosomes are even more acidic (pH ~5.0–5.5) [12,14,23]. pH-sensitive nanocomposites exploit these differences using two main strategies: incorporation of ionizable groups that undergo protonation or deprotonation, or the use of acid-labile chemical bonds (e.g., hydrazone, imine, acetal) that degrade in acidic environments [13,25].

Representative systems include micelles formed from amphiphilic polymers, which remain stable in circulation but disassemble under acidic conditions to release encapsulated drugs [25]. Polymersomes linked with hydrazone bonds have enabled the co-delivery of multiple therapeutic agents, such as curcumin and methotrexate, with synchronized release in acidic tumor compartments [۲۵]. Another important platform is metal–organic frameworks (MOFs) such as ZIF-8, which combine high drug-loading capacity with biodegradability, releasing their payload only after degrading in acidic conditions [۲٤].

These pH-responsive systems not only improve the localization of drugs but also address multidrug resistance by ensuring that high drug concentrations are achieved intracellularly [3,6,7]. Moreover, they minimize premature release during circulation, reducing systemic toxicity and enhancing therapeutic precision.

3. Multi-Stimuli Responsive Systems

Given the heterogeneity of the tumor microenvironment, single-stimulus designs often prove insufficient. To address this, multi-responsive nanocomposites have been developed that integrate responsiveness to multiple internal or external cues [3,4,5,6]. These may include combinations of pH, temperature, redox conditions, and reactive oxygen species (ROS), as well as externally applied triggers such as light, ultrasound, or magnetic fields.

A typical example involves Fe_3O_4 magnetic nanoparticles incorporated into thermosensitive hydrogels. When exposed to an alternating magnetic field, these composites generate localized heat, simultaneously inducing drug release and exerting a hyperthermic cytotoxic effect [20,21,22]. Similarly, gold nanoparticles embedded in polymers leverage their strong plasmonic absorption for near-infrared (NIR)-triggered photothermal therapy, while also enabling light-controlled drug release [15,17]. Other multifunctional systems employ ROS-cleavable linkers alongside pH-sensitive moieties, ensuring that drugs are released only when multiple tumor-specific conditions are present [14,24].

Such multi-responsive designs represent a key step toward precision medicine, reducing the likelihood of premature release, improving tumor selectivity, and offering synergistic therapeutic effects through combined drug delivery and physical tumor ablation.

4. Graphene-Based Nanocomposites

Among emerging materials, graphene oxide (GO) and its derivatives have gained attention for their unique physicochemical properties. GO provides an exceptionally high surface area for drug loading, particularly for aromatic anticancer agents via π–π stacking interactions [4,5,7]. However, pristine graphene can pose challenges in biocompatibility and dispersibility. These limitations have been overcome by functionalizing GO with biocompatible polymers such as polyethylene glycol (PEG) and polylactide (PLA), which improve stability, circulation time, and reduce toxicity [2,5].

Recent studies have highlighted the potential of GO-based nanocomposites in targeted cancer therapy. For instance, a GO/(PHEMA-g-PLA)-b-PEG-b-(PHEMA-g-PLA) nanocomposite demonstrated efficient loading of doxorubicin (~82%), pH-responsive release (accelerated at pH 5.4 vs. pH 7.4), and enhanced in vitro anticancer activity against breast cancer cells [٢٥-٢٢]. Compared with free doxorubicin, the nanocomposite exhibited superior cellular uptake, increased reactive oxygen species generation, and stronger inhibition of cancer cell migration, while reducing off-target toxicity [٢٤]. Such findings position GO nanocomposites as promising candidates for overcoming key limitations of conventional chemotherapy, including systemic toxicity and multidrug resistance.

5. Current Challenges and Future Perspectives

While stimuli-responsive nanocomposite hydrogels show remarkable promise, their clinical translation remains limited by several challenges. Biocompatibility and safety are foremost concerns, particularly regarding the long-term fate of inorganic nanoparticles and potential immunogenic responses [1–3,5,]. Scalability of synthesis is another hurdle, as uniform incorporation of nanoparticles within hydrogels is technically demanding. In addition, regulatory frameworks for complex hybrid materials are underdeveloped, slowing their progression toward clinical approval [5,6,7,16].

Future directions will likely emphasize multifunctional “theranostic” platforms that combine therapeutic delivery with real-time imaging, enabling personalized treatment monitoring [15,17]. Biomimetic strategies, such as coating nanocomposites with cancer cell membranes, may enhance immune evasion and tumor targeting [5,6,16]. The integration of artificial intelligence and computational modeling holds potential for predicting polymer behavior and optimizing drug delivery for individual patients [15]. Finally, advances in green chemistry and biodegradable materials will be essential for developing safe, sustainable, and clinically translatable nanocomposite systems [5,6].

Discussion

The advent of stimuli-responsive nanocomposite hydrogels has revolutionized the design of smart drug delivery systems by integrating the versatility of hydrogels with the multifunctionality of nanoscale reinforcements. Unlike conventional hydrogels, which often suffer from weak mechanical stability, uncontrolled swelling, and poor loading efficiency, nanocomposite counterparts provide a structurally robust and bioactive platform. The incorporation of nanofillers—such as graphene oxide, layered silicates, or metallic nanoparticles—endows the hydrogel matrix with enhanced mechanical strength, tunable porosity, and responsiveness to external or endogenous stimuli.

One of the most remarkable features of these systems is their ability to exploit the tumor microenvironment (TME) as a natural trigger for selective drug release. Tumors are typically characterized by hypoxia, acidic pH, elevated temperature, and oxidative stress. By engineering hydrogels that respond to such aberrant conditions, drug release can be localized to tumor sites while minimizing systemic side effects. For instance, pH-responsive hydrogels degrade in acidic microenvironments, releasing chemotherapeutics precisely where malignant tissues reside. Similarly, thermo-sensitive hydrogels, often based on poly(N-isopropylacrylamide), can undergo sol–gel transitions at temperatures slightly above physiological norms, thereby conferring site-specific retention and release.

A further evolution has been the development of multi-stimuli responsive systems, which integrate dual or triple trigger mechanisms (e.g., pH + temperature + redox). Such designs significantly increase precision by requiring multiple pathological cues for drug release, thus reducing the probability of premature leakage and ensuring higher therapeutic indices. Moreover, these systems can be designed for on-demand release via external stimuli such as near-infrared light, ultrasound, or magnetic fields, offering clinicians real-time control over therapy.

Graphene oxide and carbon-based nanocomposites deserve particular attention for their unparalleled drug loading capacity, photothermal conversion efficiency, and potential in combination therapies. By coupling chemotherapeutics with photothermal or photodynamic agents within a single hydrogel matrix, synergistic treatment strategies can be realized. However, concerns regarding long-term biocompatibility, oxidative stress induction, and biodegradability of graphene-based materials remain significant hurdles to clinical adoption.

Despite promising laboratory results, the translation of nanocomposite hydrogels into clinical oncology faces multiple barriers. Scalability is a major challenge, as current synthesis methods often involve batch-to-batch variability and complex fabrication steps that are not easily adaptable to industrial production. Regulatory frameworks for hybrid nanomaterials remain underdeveloped, raising concerns about reproducibility, long-term toxicity, and immunogenicity. Additionally, the heterogeneity of the tumor microenvironment complicates the predictability of stimulus-responsiveness, highlighting the need for patient-specific designs.

Looking forward, integrating artificial intelligence (AI) and computational modeling into hydrogel design may accelerate material optimization, enabling predictive control over swelling, degradation, and release kinetics. 3D bioprinting and microfluidic technologies also open exciting avenues for personalized hydrogel scaffolds that replicate patient-specific tumor architectures. Moreover, the concept of theranostics, where diagnostic imaging agents and therapeutic drugs are co-encapsulated, has the potential to transform hydrogels into “all-in-one” platforms capable of monitoring treatment response in real-time.

Ultimately, the convergence of materials science, oncology, and bioengineering is redefining the role of hydrogels in cancer therapy. While challenges related to safety, manufacturing, and regulation remain pressing, the rapid pace of innovation suggests that stimuli-responsive nanocomposite hydrogels will play a pivotal role in the next generation of precision and personalized cancer therapeutics.

Conclusion

Stimuli-responsive nanocomposite hydrogels hold immense promise as next-generation drug delivery platforms in oncology. Their capacity to harness endogenous and exogenous triggers for controlled drug release offers a paradigm shift away from conventional systemic chemotherapy, enabling personalized and precision medicine. Yet, for these technologies to move beyond experimental models, future research must address safety, manufacturing, and translational challenges. Integrating artificial intelligence-driven design, biomimetic coatings, and environmentally sustainable fabrication methods may accelerate their journey from bench to bedside. Ultimately, the convergence of nanotechnology, polymer science, and oncology positions nanocomposite hydrogels as a cornerstone of future cancer therapeutics.

REFERENCES

[1] Wu, X., Xin, Y., Zhang, H., Quan, L., & Ao, Q. (2024). Biopolymer-based nanomedicine for cancer therapy: Opportunities and challenges. *International Journal of Nanomedicine*, 19, 7415–7471.
[2] Ali, I., Alsehli, M., Scotti, L., Tullius Scotti, M., Tsai, S. T., Yu, R. S., Hsieh, M. F., & Chen, J. C. (2020). Progress in polymeric nano-medicines for theranostic cancer treatment. *Polymers*, 12(3), 598.
[3] Samadi, A. M., Yazdian, N. N., & Rashidi, M. (2021). Nanocomposite hydrogels: A promising approach for developing stimuli-responsive systems and its application in targeted drug delivery. *Shahid Sadoughi University of Medical Sciences Journal*, 29(7), 3877–3897.
[4] Karchoubi, F., & Pahlevani, H. (2019). A review of nanocomposite hydrogels: Rheology, morphology, and applications. *Journal of Applied Research of Chemical-Polymer Engineering*, 3(3), 3–38.
[5] Mondal, A., Nayak, A. K., Chakraborty, P., Banerjee, S., & Nandy, B. C. (2023). Natural polymeric nanobiocomposites for anti-cancer drug delivery therapeutics: A recent update. *Pharmaceutics*, 15(8), 2064.
[6] Alharbi, H. M. (2024). Exploring the frontier of biopolymer-assisted drug delivery: Advancements, clinical applications, and future perspectives in cancer nanomedicine. *Drug Design, Development and Therapy*, 18, 2063–2087.
[7] Andoh, V., Ocansey, D. K. W., Naveed, H., Wang, N., Chen, L., Chen, K., & Mao, F. (2024). The advancing role of nanocomposites in cancer diagnosis and treatment. *International Journal of Nanomedicine*, 19, 6099–6126.
[8] Longobardi, G., Moore, T. L., Conte, C., Ungaro, F., Satchi-Fainaro, R., & Quaglia, F. (2024). Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 16(5), e1990.
[9] Nokhodi, F., Goodarzi, M. T., & Nekoei, M. (2023). Polymer nanoparticles as a useful tool for controlled and targeted release of anticancer drugs: A review article. *New Cellular and Molecular Biotechnology Journal*, 13(50), 9–38.
[10] Karimi, M., Sahandi Zangabad, P., Ghasemi, A., Amiri, M., Bahrami, M., Malekzad, H., Ghahramanzadeh Asl, H., Mahdieh, Z., Bozorgomid, M., Ghasemi, A., Rahmani Taji Boyuk, M. R., & Hamblin, M. R. (2016). Temperature-responsive smart nanocarriers for delivery of therapeutic agents: Applications and recent advances. *ACS Applied Materials & Interfaces*, 8(33), 21107–21133.
[11] Zhao, J., Lee, V. E., Liu, R., & Priestley, R. D. (2019). Responsive polymers as smart nanomaterials enable diverse applications. *Annual Review of Chemical and Biomolecular Engineering*, 10, 361–382.
[12] Deirram, N., Zhang, C., Kermaniyan, S. S., Johnston, A. P. R., & Such, G. K. (2019). pH-responsive polymer nanoparticles for drug delivery. *Macromolecular Rapid Communications*, 40(1), 1800917.
[13] Chang, S., et al. (2021). Stimuli-responsive polymer nanoplatforms for targeted cancer therapy: Design, mechanisms and translational prospects. *Frontiers in Bioengineering and Biotechnology*, 9, 707319.
[14] Chu, S., Shi, X., Tian, Y., & Gao, F. (2022). pH-responsive polymer nanomaterials for tumor therapy. *Frontiers in Oncology*, 12, 855019.
[15] Sun, L., Liu, H., Ye, Y., et al. (2023). Smart nanoparticles for cancer therapy. *Signal Transduction and Targeted Therapy*, 8, 418.
[16] Kashyap, B. K., Singh, V. V., Solanki, M. K., Kumar, A., Ruokolainen, J., & Kesari, K. K. (2023). Smart nanomaterials in cancer theranostics: Challenges and opportunities. *ACS Omega*, 8(16), 14290–14320.
[17] Beheshtizadeh, N., Amiri, Z., Tabatabaei, S. Z., Seraji, A. A., Gharibshahian, M., Nadi, A., Saeinasab, M., Sefat, F., & Kolahi Azar, H. (2024). Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: From cancer therapy to regenerative medicine approaches. *Journal of Translational Medicine*, 22(1), 520.
[18] Koide, H., Yamaguchi, K., Sato, K., et al. (2023). Engineering temperature-responsive polymer nanoparticles that load and release paclitaxel, a low-molecular-weight anticancer drug. *ACS Omega*, 9, 1011–1019.
[19] Santhamoorthy, M., & Kim, S. C. (2023). Dual pH- and thermo-sensitive poly(N-isopropylacrylamide-co-allylamine) nanogels for curcumin delivery: Swelling–deswelling behavior and phase transition mechanism. *Gels*, 9(7), 536.
[20] Gomes, A. A., Valverde, T. M., Machado, V. D. O., da Silva, E. N., Fagundes, D. A., Oliveira, F. D. P., Freitas, E. T. F., Ardisson, J. D., Ferreira, J. M. D. F., Oliveira, J. A. D. C., & Gomes, E. R. (2023). Heating capacity and biocompatibility of hybrid nanoparticles for magnetic hyperthermia treatment. *International Journal of Molecular Sciences*, 25(1), 493.

[21] Sharifi, Z., Zamanian, M., & Ghader, B. (2019). Synthesis and characterization of cobalt-zinc ferrite magnetic nanoparticles embedded in a temperature-sensitive polymer. *Materials and Advanced Technologies*, 7(4), 51–57.
[22] Rezaei, M. (2022). A review of recent advances in iron oxide nanoparticles as a magnetic agent in cancer diagnosis and treatment. *Internal Medicine Today*, 28(3), 280–299.
[23] Bleich, N. K., Kallai, I., Lieberman, J. R., Schwarz, E. M., Pelled, G., & Gazit, D. (2012). Gene therapy approaches to regenerating bone. *Advanced Drug Delivery Reviews*, 64(12), 1320–1330.
[24] Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., & Shen, J. (2025). Development of stimuli-responsive polymeric nanomedicines in hypoxic tumors and their therapeutic promise in oral cancer. *Polymers*, 17(8), 1010.
[25] Nokhodi, F., Goodarzi, M. T., & Nekoei, M. (2023). Polymer nanoparticles as a useful tool for controlled and targeted release of anticancer drugs: A review article. *New Cellular and Molecular Biotechnology Journal*, 13(50), 9–38.